Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00324155
Registration number
NCT00324155
Ethics application status
Date submitted
8/05/2006
Date registered
10/05/2006
Date last updated
2/11/2014
Titles & IDs
Public title
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Query!
Scientific title
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Query!
Secondary ID [1]
0
0
CA184-024
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ipilimumab
Treatment: Drugs - Placebo
Treatment: Drugs - Dacarbazine
Experimental: Arm A: Ipilimumab and Dacarbazine - In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
Active Comparator: Arm B: Placebo and Dacarbazine -
Treatment: Drugs: Ipilimumab
Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent
In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression
Treatment: Drugs: Placebo
Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
Treatment: Drugs: Dacarbazine
Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from the date of randomization until the date of death. Analysis of OS was to be done once 416 deaths had occurred (primary endpoint). However, analysis occurred at 414 deaths (February 7, 2011), due to operational timing of the study. Median number of months of OS and associated confidence interval calculated using the method of Brookmeyer and Crowley.
Query!
Timepoint [1]
0
0
Date of randomization to 37 months through 5-year follow-up and up to approximately 76 months
Query!
Secondary outcome [1]
0
0
Survival Rate at 1 Year, 18 Months, 2 Years, and 3 Years
Query!
Assessment method [1]
0
0
The survival rate (percentage of participants alive) was defined as the probability that a participant is alive at 1 year (or 18 months, 2 years, or 3 years) following randomization and was estimated via the Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Date of randomization to 3 years following randomization
Query!
Secondary outcome [2]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [2]
0
0
DCR=number whose best overall response (BOR) was partial response (PR), complete response (CR) or stable disease (SD), divided by all randomized participants (unevaluable participants included). Independent review committee assessment. BOR=date of first dose to last tumor assessment prior to subsequent cancer therapy (including tumor resection, excluding palliative local radiotherapy). Modified World Health Organization criteria: CR=disappearance of all lesions; no evidence of progressive disease (PD); PR=50% or more decrease in the sum of products of the longest diameter and greatest perpendicular diameter of all index lesions compared with baseline; SD=neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD; PD=at least 25% increase in sum of products of all index lesions and/or appearance of any new lesions; nonindex lesions: appearance of any new lesions and/or unequivocal progression of nonindex lesions.
Query!
Timepoint [2]
0
0
First dose to last tumor assessment prior to subsequent therapy at data cutoff for Primary Endpoint (approximately 5 years)
Query!
Secondary outcome [3]
0
0
Median Number of Months of Progression-free Survival (PFS)
Query!
Assessment method [3]
0
0
PFS=time between randomization and date of progression or death, whichever occurs first. Participants who died without reported prior progression were considered to have progressed on date of death. For those alive and not progressed, PFS was censored on date of last evaluable tumor assessment (TA). Those who have not died and have no recorded postbaseline TA were censored at randomization. Those who died without any recorded postbaseline TA were considered to have progressed on date of death. Evaluation was conducted by both investigator and an independent review committee (IRC), who assessed radiologic imaging studies, photographs of skin lesions, and clinical data. Progressive disease defined using modified criteria of the World Health Organization: demonstration of at least a 25% increase in the sum of products of all index lesions or the appearance of any new lesions. For nonindex lesions: appearance of any new lesions or unequivocal progression of nonindex lesions.
Query!
Timepoint [3]
0
0
Randomization to date of progression or death to approximately 5 years
Query!
Secondary outcome [4]
0
0
Progression-free Survival (PFS) Rate Truncated at Week 12
Query!
Assessment method [4]
0
0
PFS rate=probability patient was progression-free at Day 78, calculated as total patients receiving treatment and with an overall response of stable disease (SD), partial response (PR), or complete response (CR) at Week 12, divided by total patients. For those alive and not progressed at or before Week 12, PFS censored on date of last evaluable tumor assessment (TA) at or before Week 12. Those with an assessment of PD prior to Week 12 and subsequent assessment of SD, PR, or CR at Week 12 were called progression-free at Week 12. Those with no recorded postbaseline TA dated on or before Day 109, and who had not died on or before Day 109, were censored at randomization. PD=at least 25% increase in sum of products of all index lesions or appearance of any new lesions. Both an investigator and independent review committee (IRC) assessed radiologic imaging studies, photographs of skin lesions, and clinical data. IRC assessment was considered primary over that of the investigators.
Query!
Timepoint [4]
0
0
Day 78
Query!
Secondary outcome [5]
0
0
Best Overall Response Rate (BORR)
Query!
Assessment method [5]
0
0
BORR=number with Best Overall Response (BOR) of complete response (CR) or partial response (PR), divided by total number of randomized patients. BOR=date of first dose to the last tumor assessment prior to subsequent cancer therapy (including tumor resection surgery but excluding palliative local radiotherapy for bone lesions). Independent review committee assessment. Modified criteria of the World Health Organization (mWHO): CR=disappearance of all lesions; no evidence of progressive disease; PR=50% or greater decrease in the sum of products of the longest diameter and greatest perpendicular diameter of all index lesions compared with baseline. Immune-related (ir) response criteria (irRC) assess tumor response in patients on immunotherapy: irCR=disappearance of all lesions in 2 consecutive observations at least 4 weeks apart; irPR=50% or greater decrease in total measureable tumor burden compared with peak in 2 observations at least 4 weeks apart.
Query!
Timepoint [5]
0
0
First dose to last tumor assessment at data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [6]
0
0
Duration of Response (DOR): Randomized Participants With Response of Complete Response (CR) or Partial Response (PR)
Query!
Assessment method [6]
0
0
DOR defined in those with Best Overall Response (BOR)=CR or PR per independent review committee (IRC) as time between date of response of confirmed CR or PR, whichever occurred first, and date of PD or death. If PR assessed before CR, DOR confirmed at earlier time-point showing PR. Modified criteria of the World Health Organization (mWHO): CR=disappearance of all lesions;no evidence of PD; PR=50% or greater decrease in the sum of products of longest and greatest perpendicular diameters (SPD) of all index lesions compared with baseline. PD=an increase of 25% or greater in SPD of index lesions compared with the smallest recorded sum, or appearance of 1 or more new lesions. Immune-related response criteria (irRC): SD=50% decrease in total measurable tumor burden compared with peak cannot be established nor 25% increase compared with nadir, in absence of unequivocal progression of nonindex lesions. Unconfirmed immune-related (ir) CR, irPR, or irPD=irSD.
Query!
Timepoint [6]
0
0
Day of CR or PR to day of PD or death up to data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [7]
0
0
Time to Response: All Randomized Participants With Response to Treatment
Query!
Assessment method [7]
0
0
Time to response was defined as the time between the first dose of study therapy and the date when measurement criteria were met for Best Overall Response (BOR) of partial response (PR) or complete response (CR), whichever occurred first, per independent review committee. Note that if an overall response of PR occurred before confirmation of CR, the time to response endpoint was not determined by the time that the BOR of CR was shown but rather by the earlier time point showing PR. Modified criteria of the World Health Organization: CR=disappearance of all lesions; no evidence of progressive disease (PD); PR=50% or more decrease in the sum of products of the longest and greatest perpendicular diameters (SPD) of all index lesions compared with baseline; PD=an increase of 25% or greater in the SPD of index lesions compared with the smallest recorded sum, or the appearance of 1 or more new lesions.
Query!
Timepoint [7]
0
0
First dose to date of BOR up to data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [8]
0
0
Duration of Stable Disease (SD): Randomized Participants With Stable Disease
Query!
Assessment method [8]
0
0
Duration of SD was defined in those whose Best Overall Response (BOR) was SD, per independent review committee (IRC) as the time between Week 12 and date of progressive disease (PD) or death , whichever occurs first. For those who underwent tumor resection following Week 12 but prior to PD, duration of SD was censored on date of last evaluable tumor assessment (TA) prior to resection. For those with BOR of SD at Week 12, date of PD was used in analysis of duration of SD. For those with BOR=SD who have not subsequently progressed and who remain alive, duration of SD censored on date of last evaluable TA. Modified criteria of the World Health Organization (mWHO): SD=insufficient decrease to qualify for partial response or sufficient increase to qualify for PD; PD=an increase of 25% or more in sum of products of longest diameter and greatest perpendicular diameter of index lesions compared with smallest recorded sum, or appearance of 1 or more new lesions.
Query!
Timepoint [8]
0
0
Week 12 to date of disease progression or death up to data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Brain Metastasis-Free Survival at Time of Data Cutoff
Query!
Assessment method [9]
0
0
Brain metastasis-free survival was defined as the time from randomization to the date of progression with a new lesion located in the brain. New brain lesions prior to Week 12 constituted a progression event (unlike main progression-free survival analysis). A participant who dies without documentation of a brain lesion was considered to have progressed with brain metastasis on the date of death. Participants who are free of brain metastasis were censored on the date of their last tumor assessment. An independent review committee evaluated images of participants with clinical symptoms to determine the number of those free of brain metastasis. The brain metastasis-free status was reported as a percent of participants (n/N), where n= participants with metastasis-free brains at data cutoff for the Primary Endpoint and N= randomized participants. A 2-sided Clopper and Pearson confidence interval was performed.
Query!
Timepoint [9]
0
0
Date of randomization up to data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [10]
0
0
Number of Participants With Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Hypersensitivity, Immune-related AEs/SAEs, and Inflammatory AEs/SAEs
Query!
Assessment method [10]
0
0
AE=any new undesirable symptom, sign, clinically significant laboratory abnormality, or medical condition occurring after starting study treatment, even if the event was not considered to be drug-related. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling. Randomization=Day 1; start of treatment (first dose)=Week 1. Summarization time frame is from first dose to 70 days after last dose of study at time of 414 deaths.
Query!
Timepoint [10]
0
0
Week 1 (First Dose) to 70 days after last dose of study up to data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [11]
0
0
Number of Participants With Grade 2-3 and Grade 3-4 Immune-related Adverse Events (irAEs) With Resolution Resolved
Query!
Assessment method [11]
0
0
irAEs included the categories: gastrointestinal (GI), diarrhea, liver, endocrine, and skin. Grade 2=moderate adverse events (AEs); minimal, local, or noninvasive intervention indicated. Grade 3=severe AEs, medically significant but not immediately life-threatening. Grade 4=life-threatening consequences; urgent intervention indicated. Resolution is defined as improvement to Grade 1 or less or to the Grade at baseline (prior to treatment).
Query!
Timepoint [11]
0
0
Week 1 (first dose) to 70 days after last dose up to data cutoff for primary endpoint (approximately 5 years)
Query!
Secondary outcome [12]
0
0
Time to Resolution of Grade 2-3, Grade 3-4 Immune-related Adverse Events (irAEs)
Query!
Assessment method [12]
0
0
irAEs included the categories: gastrointestinal (GI), diarrhea, liver, endocrine, and skin. Grade 2=Moderate adverse events (AEs); minimal, local or noninvasive intervention indicated. Grade 3=severe AEs, medically significant but not immediately life-threatening. Grade 4=life-threatening consequences; urgent intervention indicated. Time to resolution is defined as improvement to Grade 1 or less or to the Grade at baseline (prior to treatment).
Query!
Timepoint [12]
0
0
Week 1 (first dose) to 70 days after last dose up to database lock for primary endpoint (approximately 5 years)
Query!
Eligibility
Key inclusion criteria
- Informed Consent
- Measurable Disease
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- Lab / imaging requirements
- Neg for Human Immunodeficiency Virus (HIV), Hepatitis B (HepB), C
- Men and Women > 18 years (16 were allowable)
- Prior therapy restriction (adjuvant only)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion:
- Pregnant / nursing
- Inadequate contraception
- Brain metastasis
- Primary ocular or mucosal melanoma
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
681
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - Coffs Harbour
Query!
Recruitment hospital [2]
0
0
Local Institution - Newcastle
Query!
Recruitment hospital [3]
0
0
Local Institution - Port Macquarie
Query!
Recruitment hospital [4]
0
0
Local Institution - South Brisbane
Query!
Recruitment hospital [5]
0
0
Local Institution - Box Hill
Query!
Recruitment postcode(s) [1]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [2]
0
0
2300 - Newcastle
Query!
Recruitment postcode(s) [3]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [4]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Mexico
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oregon
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
South Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Buenos Aires
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Cordoba
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Santa Fe
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Vienna
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Brasschaat
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Brussels
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Edegem
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Gent
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Ceara
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Rio Grande Do Sul
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Sao Paulo
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Saskatchewan
Query!
Country [34]
0
0
Chile
Query!
State/province [34]
0
0
Santiago
Query!
Country [35]
0
0
Czech Republic
Query!
State/province [35]
0
0
Olomouc
Query!
Country [36]
0
0
Czech Republic
Query!
State/province [36]
0
0
Praha
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Cedex 1
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Cedex 2
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bordeaux
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Marseille
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Paris
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Pierre Benite
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Villejuif
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Berlin
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Heidelberg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Jena
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Kiel
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Mannheim
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Muenchen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Tubingen
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Kaposyar
Query!
Country [53]
0
0
Ireland
Query!
State/province [53]
0
0
Dublin 4
Query!
Country [54]
0
0
Ireland
Query!
State/province [54]
0
0
Cork
Query!
Country [55]
0
0
Ireland
Query!
State/province [55]
0
0
Galway
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Jerusalem
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Tel Aviv
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Genova
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Milano
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Napoli
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Padova
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Ragusa
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Rome
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Siena
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Eindhoven
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Hv Amsterdam
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Wurzburg
Query!
Country [68]
0
0
Norway
Query!
State/province [68]
0
0
Oslo
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Gdansk
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Lodz
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Lublin
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Poznan
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Wroclaw
Query!
Country [74]
0
0
Portugal
Query!
State/province [74]
0
0
Lisboa
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Stavropol
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Moscow
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Murmansk
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Ryazan
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Samara
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
St Petersburg
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
St.-Petersburg
Query!
Country [82]
0
0
South Africa
Query!
State/province [82]
0
0
Eastern Cape
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Gauteng
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Western Cape
Query!
Country [85]
0
0
South Africa
Query!
State/province [85]
0
0
Johannesburg
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Barcelona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Canarias
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Valencia
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Zaragoza
Query!
Country [90]
0
0
Switzerland
Query!
State/province [90]
0
0
Basel
Query!
Country [91]
0
0
Switzerland
Query!
State/province [91]
0
0
Geneva
Query!
Country [92]
0
0
Ukraine
Query!
State/province [92]
0
0
Cherkassy
Query!
Country [93]
0
0
Ukraine
Query!
State/province [93]
0
0
Dnepropetrovsk
Query!
Country [94]
0
0
Ukraine
Query!
State/province [94]
0
0
Lviv
Query!
Country [95]
0
0
Ukraine
Query!
State/province [95]
0
0
Uzhgorod
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Avon
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Dorset
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Essex
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Greater London
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Merseyside
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Medarex
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this clinical research study is to examine the safety and effectiveness (how
well the drug works) of two different treatments for patients with melanoma. One treatment is
an investigational compound (a drug that is not currently approved by the United States Food
and Drug Administration [FDA]), know as Ipilimumab (also known as MDX-010 or BMS-734016)
together with an approved chemotherapy drug called Dacarbazine
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00324155
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00324155
Download to PDF